Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline vs Ceftriaxone + Metronidazole in cIAI
NCT00230971Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Primary completion
- Sep 2008
- Modality
- Orthosteric Ligands
- Countries
- 19
01
Overview
Phase 4, randomised, open-label trial of tigecycline in Intra-abdominal infection (IAI) (2 arms), sponsored by Pfizer. Primary endpoint: Clinical Response of Cure at Test-of-Cure (TOC) Visit at 6 weeks. Started Oct 2005; status: completed.
02
Drugs
tigecycline
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT00230971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230971.